血清素正腎上腺素抑制劑市場:各用途，各流通管道，各地區 - 規模，佔有率，展望，機會分析，2023～2030年

Serotonin Norepinephrine Inhibitor Market, By Application, By Distribution Channel, And By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年05月16日 | 出版商:

Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

市場動態:

全球抑鬱症患者數量的增加是推動該市場增長的主要因素。根據世界衛生組織 (WHO) 的數據，世界上超過 5.0% 的人口患有抑鬱症。由於導致抑鬱症發展的各種因素，包括日益增加的社會孤立和壓力大的工作環境，預計這一數位在未來幾年還會增加。對抑鬱症有效治療的需求不斷增長也推動了該市場的增長。除此之外，COVID-19大流行的出現導致多個國家失業率上升，導致金融不穩定。結果，家庭收入減少，造成人們的壓力和焦慮。因此，抗抑鬱藥的需求不斷增加。

另一方面，藥物相關的副作用成為市場成長的妨礙。

本調查的主要特徵

本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球血清素正腎上腺素抑制劑市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
同時並提供市場推動因素和限制、機會、新產品發佈或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球血清素正腎上腺素抑制劑市場的主要參與者之企業簡介。
藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發佈、類型升級、市場擴張和營銷策略做出明智的決策。
全球血清素正腎上腺素抑制劑市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
利益相關者可以透過全球血清素正腎上腺素抑制劑市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

Pfizer Inc.
Eli Lilly and Company
Allergan Plc.
AstraZeneca Plc.
Forest Laboratories Inc.
Johnson & Johnson
Lundbeck A/S
Merck & Co., Inc.
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Wyeth Pharmaceuticals Inc.
Zydus Cadila Healthcare Ltd.

第9章章節

調查手法
關於出版社

簡介目錄

Product Code: CMI5718

Medications called serotonin norepinephrine inhibitors are similar to other antidepressant medications known as selective serotonin reuptake inhibitors (SSRIs). They both ease depression by affecting communication between brain nerve cells. However, SNRIs focus on two important brain chemicals-neurotransmitters-instead of just one. Serotonin norepinephrine inhibitors were developed in the mid-1990s and are prescribed to treat depression, anxiety disorders, and chronic pain, including neuropathic pain from diabetes or other chronic nerve conditions. They differ from SSRIs in that they also impact the levels of norepinephrine, which is involved with pain signals to body.

Market Dynamics:

The rise in the number of people suffering from depression globally is a major factor driving the growth of this market. According to World Health Organization, over 5.0% of the worldwide population suffers from depression. This number is expected to increase in the coming years, owing to various factors such as increasing social isolation and stressful work environment, which leads to the development of depression. The increase in the demand for effective treatment of depression is also propelling the growth of this market. In addition to this, the emergence of COVID-19 pandemic has increased the unemployment rate in several countries and has led to financial instability. This has resulted in a decrease in the household income, which is causing stress and anxiety among people. This in turn is increasing the demand for antidepressant drugs.

On the other hand, side effects associated with the drugs is expected to hamper the market growth.

Key features of the study:

This report provides in-depth analysis of the global serotonin norepinephrine inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global serotonin norepinephrine inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Allergan Plc., AstraZeneca Plc., Forest Laboratories Inc., Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wyeth Pharmaceuticals Inc., and Zydus Cadila Healthcare Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global serotonin norepinephrine inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global serotonin norepinephrine inhibitor market

Detailed Segmentation:

Global Serotonin Norepinephrine Inhibitor Market, By Application
- Depression
- Anxiety Disorders
- Chronic Pain
Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Serotonin Norepinephrine Inhibitor Market, By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Company Profiles
- Pfizer Inc.
- Eli Lilly and Company
- Allergan Plc.
- AstraZeneca Plc.
- Forest Laboratories Inc.
- Johnson & Johnson
- Lundbeck A/S
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Wyeth Pharmaceuticals Inc.
- Zydus Cadila Healthcare Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Geography
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rise in the number of people suffering from depression
Increase in the demand for effective treatment of depression
- Restraints
Side effects associated with the medication
- Opportunities
Growing awareness regarding depression
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Serotonin Norepinephrine Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Serotonin Norepinephrine Inhibitor Market, By Application, 2017-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Bn)
Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Bn)
Chronic Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Bn)

6. Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel, 2017-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion)

7. Global Serotonin Norepinephrine Inhibitor Market, By Region, 2017-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2017 - 2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn)
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2017-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn)

8. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Allergan Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Forest Laboratories Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Wyeth Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Zydus Cadila Healthcare Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views